Trials / Recruiting
RecruitingNCT04224636
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (estimated)
- Sponsor
- Ludwig-Maximilians - University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous treatment with TACE and Atezo/Bev in the treatment of unresectable HCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Atezolizumab Injection, Bevacizumab Injection | Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE |
Timeline
- Start date
- 2020-06-10
- Primary completion
- 2025-03-01
- Completion
- 2025-03-01
- First posted
- 2020-01-13
- Last updated
- 2024-06-14
Locations
7 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04224636. Inclusion in this directory is not an endorsement.